External Source

Dr. Van Tilburg On Larotrectinib In Trk+ Pediatric Cancers

2019 0:52
Synopsis
Cornelis M. van Tilburg, MD, PhD, pediatric oncologist, Hopp Children's Cancer Center Heidelberg, discusses the activity of ...

You Might Also Like

Cornelis van Tilburg, ASCO 2019 - Larotrectinib in pediatric TRK fusion cancer 5:21
Cornelis Van Tilburg, Asco 2019 - Larotrectinib In Pediatric...
2019
Updated Response Findings With Larotrectinib in TRK+ Cancers 1:06
Updated Response Findings With Larotrectinib In Trk+ Cancers
2018
Larotrectinib in adult and pediatric patients with TRK fusion-positive primary CNS tumors 3:18
Larotrectinib In Adult And Pediatric Patients With Trk Fusio...
2021
NTRK Gene Fusions: Rare Yet Actionable 2:39
Ntrk Gene Fusions: Rare Yet Actionable
2018
Larotrectinib, a TRK inhibitor for patients with solid tumors 1:15
Larotrectinib, A Trk Inhibitor For Patients With Solid Tumor...
2021
Dr. Drilon on Activity of Larotrectinib in TRK Fusion–Positive NSCLC 1:35
Dr. Drilon On Activity Of Larotrectinib In Trk Fusion–posi...
2019
The impact of TRK inhibitor LOXO-101 (larotrectinib) on patients with TRK fusion cancers 0:52
The Impact Of Trk Inhibitor Loxo-101 (larotrectinib) On Pati...
2017
NTRKers Pediatric Webinar: NTRK Gene Fusions: A Cancer Driver In Childhood Tumors 1:25:34
Ntrkers Pediatric Webinar: Ntrk Gene Fusions: A Cancer Drive...
2021
Updated Data With Larotrectinib in TRK Fusion-Positive Solid Tumors 1:20
Updated Data With Larotrectinib In Trk Fusion-positive Solid...
2019
Larotrectinib treatment of advanced TRK fusion thyroid cancer 2:21
Larotrectinib Treatment Of Advanced Trk Fusion Thyroid Cance...
2020
Copy of Dr. Drilon Discusses the FDA Approval of Larotrectinib 0:21
Copy Of Dr. Drilon Discusses The Fda Approval Of Larotrectin...
2018
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.